Jingfeng Pharmaceutical(SZ:000908) Zheng Quan Zhi Xing·2025-08-24 16:16Core Viewpoint - Hunan Jingfeng Pharmaceutical Co., Ltd. reported a decline in revenue and net profit for the first half of 2025, indicating ongoing financial challenges and a need for strategic adjustments [2][5]. Financial Performance - The company's operating revenue for the reporting period was approximately 202.58 million yuan, a decrease of 9.47% compared to the same period last year [2][3]. - The net profit attributable to shareholders was approximately -33.05 million yuan, reflecting a slight improvement of 1.47% year-on-year [2][3]. - The net profit after deducting non-recurring gains and losses was approximately -26.50 million yuan, down by 12.50% from the previous year [2][3]. - The basic and diluted earnings per share were both -0.0370 yuan, showing a 1.60% increase compared to the previous period [3]. Cash Flow and Assets - The net cash flow from operating activities was -1.67 million yuan, a significant decline of 110.18% compared to the previous year [3]. - Total assets at the end of the reporting period were approximately 939.98 million yuan, down 3.82% from the previous year [3]. - The net assets attributable to shareholders decreased by 39.79% to approximately 81.80 million yuan [3]. Debt and Compliance - The company has faced issues with bond repayments, with overdue principal amounting to approximately 29.46 million yuan, triggering a default situation [3][4]. - The company has entered into multiple extension agreements with bondholders, with the latest extension set until June 30, 2024 [3][4]. Shareholder Information - The top ten shareholders include individuals and state-owned entities, with the largest shareholder holding 13.74% of the shares [4]. - There were no changes in the controlling shareholder or actual controller during the reporting period [4][5]. Important Matters - No significant changes in the company's operational situation were reported during the period [5].